Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00918216 · ClinicalTrials.gov registry record

Spectroscopy of Breast Tissue

A clinical trial of Breast Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
141
Enrollment target
1
Study location

NCT00918216: Completed study of Breast Cancer, sponsored by Case Comprehensive Cancer Center.

NCT00918216 is a study of Breast Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 141 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00918216, a study of Breast Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
141 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Diagnostic procedures, such as laser spectroscopy, may help find and diagnose breast cancer. PURPOSE: This phase I trial is studying laser spectroscopy to see how well it works in diagnosing breast cancer in women with breast lesions.

Primary Outcome

The data will be taken with a portable spectroscopy system that can perform fluorescence, reflectance and Raman spectroscopy simultaneously through a single fiber optic probe.

Conditions Studied

Interventions

  • OTHER medical chart review
  • OTHER immunohistochemistry staining method
  • GENETIC fluorescence in situ hybridization
  • PROCEDURE fluorescence spectroscopy
  • PROCEDURE histopathologic examination

Study Locations (1)

Ohio

  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2008-03
Est. Completion 2013-10
Case Comprehensive Cancer Center

407 total trials

What the finished NCT00918216 record still lists

NCT00918216 is an observational study that tracks outcomes without assigning an intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which medical chart review is the first listed.

NCT00918216 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00918216 about?

NCT00918216 is a clinical study titled "Spectroscopy of Breast Tissue". RATIONALE: Diagnostic procedures, such as laser spectroscopy, may help find and diagnose breast cancer. PURPOSE: This phase I trial is studying laser spectroscopy to see how well it works in diagnosing breast cancer in women with breast lesions.

What is the current status of trial NCT00918216?

This trial is currently completed. The enrollment target is 141 participants. The study started on 2008-03. Estimated completion is 2013-10.

What conditions does trial NCT00918216 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00918216?

The interventions under investigation include: medical chart review (OTHER), immunohistochemistry staining method (OTHER), fluorescence in situ hybridization (GENETIC), fluorescence spectroscopy (PROCEDURE), histopathologic examination (PROCEDURE).

Who is sponsoring clinical trial NCT00918216?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00918216 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00918216's enrollment target sits among peer trials

141 462nd of 1224 higher than 762 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03042962 · 141 participants

    Brain Networks in Dystonia

  • NCT04378439 · 141 participants · NA

    Appalachian Partnership to Reduce Disparities (Aim 2)

  • NCT04775485 · 141 participants · Phase 2

    A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  • NCT05040360 · 141 participants · Phase 2

    Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00918216, the US trial registry maintained by the National Library of Medicine. NCT00918216 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.